SK74697A3 - Tachykinin antagonists, preparation method thereof and pharmaceutical composition containing the same - Google Patents

Abstract

Compounds of formula (I), wherein R1 is mono- or di-substituted phenyl, n is zero or 1, X1 is oxygen, sulfur or =NCN, X2 and X3 are oxygen or sulfur, R2 is hydrogen or methyl, R3 is phenyl, halo-substituted phenyl, 2-naphthyl, IH-indol-3-yl or 1-methyl-indol-3-yl, Z is -N(CH3)- or -CH2-, R4 is phenyl, 3,5-bis(trifluoromethyl)phenyl or pyridyl and R5 is hydrogen, phenyl 3,5-bis(trifluoromethyl)phenyl or pyridyl, whereby, when X3 is sulfur, Z is -N(CH3)- and acid addition salt thereof have tachykinin antagonist activity and are useful as pharmaceuticals, e.g. for the treatment of pain.

Description

Technical field

The invention relates to novel compounds having tachykinin antagonist activity, processes for their preparation, pharmaceutical compositions containing them and their use as medicaments.

SUMMARY OF THE INVENTION

The present invention provides compounds of formula I

In which

R ¹ is phenyl mono- or di-substituted with one or two substituents selected from the group consisting of halogen, nitro, cyano, trifluoromethyl, hydroxy, methoxy, hydroxymethyl, methoxymethyl, methoxycarbonyl, carbamoyl, N-methyl, n is zero or 1,

X ¹ is oxygen, sulfur or = NCN,

X ² and X ³ are each independently O or S,

R ² is H or methyl,

R ³ is phenyl, halogen-substituted phenyl, 2-naphthyl, 1H-indol-3-yl or 1-methylindol-3-yl,

Z is -N (CH ₃ ) - or -CH ₂ -,

R ⁴ is phenyl, 3,5-bis (trifluoromethyl) phenyl or pyridyl; and

R ⁵ is hydrogen, phenyl, 3,5-bis (trifluoromethyl) -phenyl, or pyridyl. wherein when X ³ is a sulfur atom, Z is -N (CH ₃ ) -, or an acid salt thereof.

Halogen means chlorine, fluorine, bromine and iodine.

When R ¹ is a disubstituted phenyl group, the substituents may be the same or different.

In the group of compounds of formula IR ¹ , the phenyl group is mono- or di-substituted with one or two substituents selected from the group consisting of nitro, cyano, trifluoromethyl, carbamoyl and N-methylcarbamoyl.

2. In another group of compounds of Formula I, n is zero.

2a. When n is zero, R ¹ is preferably phenyl mono- or di-substituted with one or two substituents selected from the group consisting of nitro, cyano, methoxy and N-methylcarbamoyl (e.g., nitro, cyano, methoxymethyl, carbamoyl and N- methylcarbamoyl), in particular nitro and methoxymethyl, and in particular nitro.

2b. If n is zero, R ¹ is preferably a monosubstituted phenyl group, especially a phenyl group monosubstituted at the 2-position.

2c. When n is zero, R ¹ is most preferably a phenyl group monosubstituted in the 2-position by any of the substituents listed in paragraph 2a above, especially

2-nitrophenyl and 2- (methoxymethyl) phenyl, in particular 2-nitrophenyl.

3. In another group of compounds of the invention, n is 1.

3a. When n is 1, R ¹ is preferably a phenyl group mono- or di-substituted with one or more substituents selected from the group consisting of a halogen atom, a trifluoromethyl group and a methoxy group, in particular a halogen atom and a trifluoromethyl group.

3b. When n is 1, R ¹ is most preferably a phenyl group monosubstituted in position or disubstituted in positions 2 and 6.

3c. When n is 1, R ¹ is most preferably a phenyl group monosubstituted in position 2 or disubstituted in positions 2 and 6 by any of the substituents mentioned in paragraph 3a above, especially a phenyl group monosubstituted. in the 2-position, especially 2-halophenyl or 2-trifluoromethylphenyl, in particular 2-chlorophenyl, or

2-trifluoromethylphenyl and especially 2-chlorophenyl.

In the compounds of formula I

Preferably, n is zero.

Preferably X ¹ is an oxygen or sulfur atom, in particular an oxygen atom.

Preferably, X ² and X ^{3 are} each oxygen.

Preferably R ² is hydrogen.

8. When R ³ is a halogen-disubstituted phenyl group, it is preferably

3,4-dihalophenyl. A preferred halogen atom is chlorine, R ³ is therefore especially 3,4-dichlorophenyl.

9. Preferably R ^{3 is} 2-naphthyl or halogen, especially halogen-substituted phenyl, for example as defined in paragraph 8 above, especially 2-naphthyl.

10. Z is preferably -N (CH ₃ ) -.

If R ⁵ is other than hydrogen, R ⁴ and R ⁵ are preferably the same.

12.. Pyridyl such as R ⁴ and / or R ⁵ is preferably 2-pyridyl.

13. R ⁴ is preferably a phenyl group.

14. R ⁵ is preferably a hydrogen atom.

15. Most preferably, R ^{4 is} phenyl and R ⁵ is hydrogen.

Accordingly, the present invention includes compounds of formula I wherein R ¹ to R ⁵ , X ¹ to X ³ , for Z mean any combination or sub-combination of the meanings given in Formula I and / or in one or more of paragraphs 1 to 5 15 as above.

A. In a subset of compounds of the present invention

R ¹ is 2-halophenyl or 2-nitrophenyl, n is zero,

X ² and X ³ are each oxygen,

R ⁴ is phenyl or pyridyl,

R ⁵ is hydrogen, phenyl or pyridyl;

X ¹ , R ² , R ³ and Z have the meanings given in formula I.

B. In another sub-group of compounds of the present invention, R ¹ is a group of formula Ia wherein R ^1a is a trifluoromethyl group, a halogen atom, a methoxy group or a nitro group and

R ^1b is hydrogen, trifluoromethyl, halogen, methoxy or nitro, n is 1,

X ² and X ³ are each oxygen,

R ³ is halogen substituted phenyl, 2-naphthyl,

H-indol-3-yl or 1-methylindol-3-yl,

- Z is -N (CH ₃ ) -a

X ¹ , R ² , R ⁴ and R ⁵ have the meanings given in formula I.

Preferred meanings of the substituents in the aforementioned subgroups A and B are those mentioned in paragraphs 1 to 15 above.

Compounds of formula I wherein R ⁴ and / or R ⁵ is a pyridyl group exist in free form and in acid salt form. Of course, the present invention encompasses both the free compounds of Formula I and their acid salts.

Suitable pharmaceutically acceptable acid salts for use according to the invention are, for example, hydrochlorides.

The compounds of the invention contain two asymmetric carbon atoms (indicated in formula (I) (a) and (b)). If R ⁴ and R ⁵ are different and R ⁵ is other than hydrogen, another asymmetric carbon atom is present [(c)]. The compounds thus exhibit optical isomerism.

The individual isomers may be obtained in a conventional manner, for example by synthesis using optically active starting materials or by resolution of the initially obtained isomeric mixtures, for example by means of chromatographic techniques using a chiral carrier or by recrystallization of diastereoisomeric salts.

Of course, the present invention includes as individual isomers in pure or substantially pure form, as well as mixtures, for example racemic and diastereoisomeric mixtures, unless otherwise indicated.

In formula I, each of the carbon atoms (a) and (b) preferably has the (S) -configuration. Even more preferably, both the carbon atom (a) and the carbon atom (b) have the (S) -configuration. Accordingly, compounds of formula I as defined above are preferred wherein the carbon atoms (a) and (b) have both the (S) -configuration and are in a pure or substantially pure form, for example containing less than 10%, preferably less than 5%, for example less than 2%, of other isomeric forms.

The invention further provides a process for the preparation of a compound of formula I as defined above, or an acid salt thereof, comprising reacting a compound of formula II

(II) wherein R ² to R ⁵ , X ² , X ³ and Z are as defined above, with a compound of formula III

R ¹ '- (CH ₂ ) -N = C = X ¹ (III) wherein

R ¹ 'is phenyl, mono- or di-substituted with one or two substituents selected from the group consisting of halogen, nitro, cyano, trifluoromethyl, protected hydroxy, methoxy, protected hydroxymethyl, methoxymethyl or methoxycarbonyl and n and X ¹ have the meaning of X ¹ wherein R ¹ 'is a phenyl group substituted by a protected hydroxy group and / or a protected hydroxymethyl group, and / or a compound so obtained is obtained, wherein R ¹ ' is a phenyl group substituted with a methoxycarbonyl group, to the corresponding compound wherein R ¹ 'is a phenyl group substituted with a carbamoyl group or an N-methylcarbamoyl group, and the compound of formula I obtained is isolated in free form or in acid salt form.

The reaction of the compounds of the formula II with the compounds of the formula III is preferably carried out in an inert organic medium, for example dioxane, at a temperature of from 20 ° C to the boiling point.

The protecting groups which protect the hydroxy or hydroxymethyl groups in the substituent R ¹ 'may be any oxy-protecting groups as known and commonly used in the art of peptide chemistry, for example tert-butyldimethylsilyloxymethyl. Deprotection can be carried out by standard procedures, for example as described herein in Examples 18 and 19.

Conversion of the methoxycarbonyl group can also be accomplished by standard procedures known in the art, for example by hydrolysis to a carboxy group, converting the carboxy group to a reactive functional derivative, for example a carbonyl halide or mixed anhydride, and reacting the derivative with ammonia or methylamine, for example as further described in Examples 15 and

16th

The starting compounds of formula III are known in the art, commercially available or obtainable analogously to known compounds, for example in the case of compounds of formula III wherein X is = NCN according to the general procedures described in Example 4 herein.

Compounds of formula II can be prepared according to the following reaction scheme:

, ² '<r ^p 3 * ¹ 1 1 II N - CH -C-R ch ₃ 1 from ^R ' p 1 HN-CH l \ or ^X R ⁵ HalMg-CH, -CH R (IV) (Va) (Vb) with R (A) x '” r * ''' ² in ¹ 1 1 í Z ^R R N-- CH-C-Z-CH. (VI) R R ³ (B) I r FROM ' FS · T 1 1 ií / ^R H N --- CH-C-Z-C w (VII) R

r _d -n — ch-cr. 1 ^(c)

O * (VIII)

(d) (IX) τ

(II) wherein R _p is an amino protecting group, R _a is a carboxy-activating group, Hal is a chlorine, bromine or iodine atom, especially a bromine atom, and R ² to R ⁵ , X ² , X ³ and Z have the meanings given above .

Suitable amino protecting groups in _Rp are any groups known and used in peptide synthesis, for example the tert-butoxycarbonyl group (Boe) is particularly suitable for compounds of formulas IV and VIII.

Reaction of compounds of formula IV with compounds of formulas Va and Vb yields compounds of formula VI (and thereby compounds of formula II) wherein Z is -N (CH ₃ ) - and optionally -CH ₂ Suitable carboxy-activating groups in R ^and the reaction of a compound of formula IV with a compound of formula Va as well as step (c), the mixed anhydride groups are activated, for example isobutoxycarbonyloxy. The reaction may be carried out by methods known from peptide chemistry, for example according to the general procedure of Example 1A.2.

The starting compounds of the formulas Va and Vb are known or can be prepared analogously to known compounds, for example as described in Examples 5, 20 and 24 herein.

Suitable carboxy-activating groups in R ^and the reaction of a compound of formula IV with a compound of formula Vb are ester groups derived from pyridyl and picolyl, for example 2-pyridyloxy. The reaction can be carried out by known methods for generating the Grignard reagents of formula Vb in situ, for example as described herein in Example 28.

The starting compounds of the general formula (IV) are known or described in the prior art or can be prepared by known methods, for example by activation of the corresponding N-protected acids, preferably in situ, for example as described herein in Example 1 A.1.

Alternatively, compounds of formula II wherein R ² is methyl can be prepared from compounds of formula IV wherein R ² is hydrogen and carrying out a methylation intermediate, for example a compound of formula IX before step (d), according to the procedure described by Olsen J. Org. Chem., 35, 1912-1915 (1970). This procedure is shown in Examples 27 and 29.

Process steps (b) and (d) are conventional deprotection procedures as are commonly performed in peptide synthesis, for example as described herein in Example IB.

The following examples illustrate the preparation of the compounds of the invention in more detail.

DETAILED DESCRIPTION OF THE INVENTION

Example 1

Preparation of 2-nitrophenylcarbamoyl - [(S) -prolyl] - [(S) -3- (2-naphthyl) -alanyl] -N-benzyl-N-methylamide [Formula I wherein R ¹ is 2-nitrophenyl, n is zero, X ¹ , X ² and X ³ are each oxygen, R ² is H, both carbon atoms (a) and (b) have an S-configuration.

To (S) -prolyl- (S) -3- (2-naphthyl) alanyl-N-benzyl-N-methylamide (1.39 g) in ethyl acetate (15 mL) was added 2-nitrophenylisocyanate (551 g). The yellow solution was stirred at room temperature for 1 hour. The reaction mixture was concentrated. The orange residue was purified by flash chromatography (2: 1 ethyl acetate: hexane) to give a yellow foam. This foam was dissolved in ethyl acetate (20 mL) and slowly added dropwise to a stirred solution of hexane (200 mL). The yellow precipitate was filtered off and dried to give the title compound, m.p. 79-82 ° C. TLC (silica gel, cyclohexane / ethyl acetate 1: 2) R f = 0.36.

Example 2

preparation

2-chlorobenzothiocarbamoyl - [(S) -prolyl] - [(S) -3- (2-naphthyl) alanyl] -N-benzyl-N-methylamide [Formula I wherein R ¹ is 2-chlorophenyl, n is 1, X ¹ is a sulfur atom, X ² and X ³ are both oxygen atoms, R ² is H, R ³ is 2-naphthyl, Z is -N (CH ₃ ) -, R ⁴ is phenyl and R ⁵ is H, both carbon atoms (a) and (b) have the S-configuration. J (S) -prolyl- (S) -3- (2-naphthyl) alanyl-N-benzyl-N-methylamide (1.03 g) is dissolved in 10 mL CH ₂ Cl ₂ with 2-chlorobenzylisothiocyanate (455 mg) and the solution was stirred at room temperature for 18 hours. The solvent was removed under reduced pressure. The product was purified by flash chromatography (silica gel, cyclohexane / ethyl acetate 1: 2) and recrystallized from ethyl acetate to give fine white needles. These were filtered and dried at 13.3 Pa at 75 ° C for 18 hours to give the title compound, mp 129-131 ° C, TLC (silica gel, cyclohexane / ethyl acetate 1: 2) R f = 0.3 .

The following compounds of formula Ia were prepared

(Ia) wherein R ² is hydrogen, R ³ is 2-naphthyl, and Z is -N (CH ₃ ) -, analogously to Example 1 (when n is zero) or Example 2 (when n is 1).

pr. R ^<a n X * R R ³ phys. data mp (° C) / Rf 3 2-NO ₂ zero with phenyl H 118-121 / 0.45 ° ' 4 * 2-NO ₂ zero NCN phenyl H 92-96 / 0.10 ¹¹¹ 5. : 2-NO / zero 0th 2-pyridyl 2-pyridyl 90-92 / 0.18 ° ' 6 2 -NO ₂ zero 0 2-pyridyl H 69-71 / 0.01 ° ' 7 2-NO ₂ zero with 2-pyridyl H 98-100 / 0.01 ° ' 8 2-C1 zero with phenyl H 94-98 / 0.04 ° ' 9 4-NO ₂ zero 0 phenyl H 126-129 / 0.20 ° ' 10 2-CN zero 0 phenyl H 124-126 / 0.25 ° ' 11 3-CN zero 0 phenyl H 105-107 / 0.15 ° ' 12 4 -F zero 0 phenyl H 85-87 / 0.28 ° ' 13 2- (CH3OCO) zero 0 phenyl H 50-60 / 0.23 ° ' 14 3 -NO ₂ zero 0 phenyl H 98-101 / 0.25 ° ' 15 ** 2- (CH 3 NHCO) zero 0 phenyl H 96-102 / 0.19 ° ' 16 ** 2- (NH3CO) zero 0 phenyl H 109-115 / 0.10 ° ' ¹⁷ 2- (CH 3 OCH 3) zero 0 phenyl • H 58-62 / 0.27 ° ' 18 *** 2-HO zero 0 phenyl H ' 98-104 / 0.24 ° ' 19 *** 2- (HOCH ₂ ) zero 0 phenyl H 83-86 / 0.20 ° ' 20 2-C1 1 with 2-pyridyl 2-pyridyl 95-97 / 0.09 ° ' 21 2-C1 1 with 2-pyridyl H 85-87 / 0.01 ° ' 22 2-CF3 1 with phenyl H 175-176 / 0.19 ° ' 23 2-C1 1 0 phenyl H 69-73 / 0.18 ° ' 24 2-C1 1 with ^cr 3 H 125-127 / 0.11 ° ' 25 2-C1 1 with phenyl phenyl 102-104 / 0.15 ° ' 26 2-Br 1 with phenyl H 142-143 / 0.45 ° '

The following compounds of formula Ia above, wherein R ^1a is 2-NO ₂ , R ³ is 2-naphthyl, R ⁴ is phenyl and R ⁵ is H, can be prepared analogously to Example 1 (when n is zero) or according to of Example 2 (when n is 1).

pr. n R ^J FROM phys. data 1.1. C / R 27 zero ABOUT ch ₃ N (CH ₃ ) 71-74 / 0.55 ^(Z) 28 zero ABOUT H ch ₂ 106-108 / 0.35 ^w 29 1 with ch ₃ N (CH ₃ ) 84-85 / 0.19 ^w . '

The following compounds of general formula Ia above, wherein R ^{1 3} is hydrogen, Z is -N (CH ₃ ) -, R ⁴ is phenyl and R ⁵ is hydrogen can be prepared analogously to Example 1 (when n is zero) ) or according to Example 2 (when n is 1).

· pr _RLA n X ¹ R phys. mp ° C / Rf 30 2-NOZ zero ABOUT 1H-Indol-3-yl 96-98 / 0.36 ^(Z) 31 2-NO2 zero ABOUT 3,4-dichlorophenyl 151-152 / 0.54 ^(Z) 32 2-Cl 1 with 3,4-dichlorophenyl 185-186 / 0.59 ^w 33 2-Cl 1 with 1-methyl-indol-3-yl 160-162 / 0.06 ⁽³⁾

(1) = silica gel, cyclohexane / ethyl acetate 1: 2 (2) = silica gel, cyclohexane / ethyl acetate 1: 4 (3) = silica gel, CH2Cl2 / CH3OH 25: 1 (4) = silica gel, cyclohexane / ethyl acetate 1: 1 * Na To prepare the compound of Example 4, the starting compound of Formula III is prepared in situ as follows:

To cyanamide (44 mg) in dimethylformamide (5 mL) was added potassium tert-butoxide (1 mL, 1 M in tetrahydrofuran). A white precipitate is formed. The reaction mixture was stirred at room temperature for 20 minutes. 2-Nitrophenylisothiocyanate (180 mg) was added as a solid and the reaction mixture was stirred at room temperature for 10 minutes. The mixture was ice-cooled and triethylamine (0.42 mL) was added followed by (S) -prolyl- (S) -3- (2-naphthyl) alanyl-N-benzyl-N-methylamide (415 mg) and HgCl ₂ ( 300 mg). The reaction is continued as in Example 1, including the treatment of the prepared compound.

** The compounds of Examples 15 and 16 were prepared via the compound of Example using the following additional steps:

The product of Example 13 is hydrolyzed to give the corresponding acid wherein R ^1a (Formula Ia) is 2- (HOCO) -. This acid is then reacted with isobutyl chloroformate and N-methylmorpholine in ethyl acetate under standard conditions (the temperature is below -15 ° C), slowly adding anhydrous methylamine (to prepare the compound of Example 15) or gaseous into the reaction vessel over 30 minutes. ammonia (to prepare the compound of Example 16). The crude products obtained are worked up analogously to the procedure described in Example 1.

*** The compounds of Examples 18 and 19 are prepared via an O-protected intermediate, for example, as follows:

(S) -prolyl- (S) -3- (2-naphthyl) alanyl-N-benzyl-N-methylamide is reacted with

2- (tert-butyldimethylsilyloxy) phenyl isocyanate or with 2- (tert-butyldimethylsilyloxymethyl) phenyl isocyanate analogously to Example 1 and the compounds of Examples 18 and 19 are protected in a protected form with a tert-butyldimethylsilyl group. under standard conditions using tetrabutylammonium fluoride in tetrahydrofuran.

The starting compound for the procedure of Example 1 was prepared as follows.

Example 1A [step (a)]

1A.1. Preparation of Boc- (S) -3- (2-naphthyl) alanine-isobutoxyformyl anhydride (Formula IV, R _pB Boe, R ^{2 =} H, R ³ = 2-naphthyl, X ³ = O, R ⁴ = isobutoxycarbonyloxy)

Boc- (S) -3- (2-naphthyl) alanine (480 mg) was dissolved in 5 mL of anhydrous CH ₂ Cl ₂ with N-methylmorpholine (170 µΙ, 156 mg) and cooled to -15 with stirring under nitrogen. ° C in a salt ice bath. Isobutyl chloroformate (200 µL, 20 mg) in 2 mL of anhydrous CH ₂ Cl ₂ is added dropwise, ensuring that the temperature remains below -10 ° C, and the reaction mixture is stirred for 30 minutes.

1A.2. Preparation of Boc- (S) -3- (2-naphthyl) alanyl-N-benzyl-N-methylamide (Formula VI,

R _p = Boe, R ² = H, R ³ = 2-naphthyl, X ³ = O, Z = -N (CH ₃ ) -, R ⁴ = phenyl, R ⁵ = H).

N-Benzylmethylamine (Formula Va) (185 mg) in 2 mL of anhydrous CH ₂ Cl ₂ was added dropwise to the product of Example 1A.1, again ensuring that the temperature remained below -10 ° C, and the reaction mixture was stirred until completion of the reaction by TLC. The reaction mixture was diluted to 75 mL of CH ₂ Cl ₂ and washed with 50 mL of dilute aqueous HCl, 50 mL of water and 25 mL of brine. The organic phase was dried over magnesium sulfate, filtered and the solvent was removed under reduced pressure. The product was purified by flash column chromatography (silica gel, cyclohexane / ethyl acetate 4: 1) to give the title compound as a colorless foamy solid: TLC (silica gel, cyclohexane / ethyl acetate 1: 1) Rf = 0.54.

Example 1B [step (b)]

Preparation of (S) -3- (2-naphthyl) alanyl-N-benzyl-N-methylamide (Formula VII)

The product of Example 1A (600 mg was dissolved in 10 mL 4.0 M HCl in dioxane and stirred at room temperature for about 30 minutes. HCl and dioxane were removed under reduced pressure and the residue was dissolved in 100 mL water, basified with 2 M NaOH (aq) and extracted with CH ₂ Cl ₂ (2 x 75 mL) The organic phase was dried over MgSO 4, filtered and the solvent was removed under reduced pressure to give the title compound as a yellow oil: TLC (silica gel, CH ₂ Cl ₂ / CH ₃ OH / CH ₃ COOH 90: 9: 1) R f = 0.43.

Example 1C [step (c)]

Preparation of Boc- (S) -prolyl- (S) -3- (2-naphthyl) alanyl-N-benzyl-N-methylamide (Formula IX, R _P = Boc)

The title compound was prepared analogously to Example 1A.2 by reaction of Boc- (S) -proline (310 mg) with the product of Example 1B (460 mg) to give a viscous oil: TLC (silica gel, cyclohexane / ethyl acetate 1: 1) Rf = 0.18.

Example 1D [step (d)]

Preparation of (S) -prolyl- (S) -3- (2-naphthyl) alanyl-N-benzyl-N-methylamide (Formula II)

The title compound was prepared in analogy to Example 1B starting from the product of Example 1C (740 mg) and obtained as a foamed solid: TLC (silica gel, CH 2 Cl 2 / CH 3 OH / CH 3 COOH 90: 9: 1) R f = 0.29.

The product of Example 1D is also used as a starting material for the preparation of the compounds of Examples 2 to 4, 8 to 19, 22, 23 and 26 and the starting materials of Formula II for Examples 6, 7, 21, 25 and 30 to 33 are prepared analogously. . The starting materials of formula II for Examples 5, 20, 24 and 27 to 29 are prepared analogously to Examples 1A to 1D using the following means to obtain a starting material of formula Va and / or the procedure is adapted:

Concerning examples 5 and 20:

Preparation of N-methyl- (di-2-pyridyl) methylamine (formulas Va, R ⁴ and R ⁵ are both

2-pyridyl)

Di-2-pyridyl ketone (2.00 g) was dissolved in 20 mL of CH ₂ Cl ₂ . Heptamethyldisilazane (1.90 g) was added followed by trimethylsilyltrifluoromethanesulfonate (0.12 g) and the reaction mixture was heated at reflux for 12 hours. The solvent was removed under reduced pressure. The crude oil (2.14 g) was dissolved in 20 mL of anhydrous C ₂ H ₅ OH. Add 0.65 g of acetic acid followed by sodium cyanoborohydride (0.68 g) and stir the reaction mixture at room temperature for 1 hour. A 1% KHSO ₄ solution is then added until the pH of solution 2 is reached, and then a 2 M NaOH solution is added until the pH of solution 12. The ₂ H ₅ OH is removed under reduced pressure and the product is extracted into ethyl acetate. The organic layer was dried over MgSO ₄ , filtered, and HCl was bubbled through the filtrate. The title compound obtained as the trihydrochloride salt is filtered off and dried for the next reaction in analogy to Examples 1A to 1D.

Concerning Example 24:

Preparation of N-methyl-3,5-bis (trifluoromethyl) benzylamide (Formula Va, R ⁴ = 3,5-bis (trifluoromethyl) phenyl, R ⁵ = H)

Step N-Boc-3,5-bis (trifluoromethyl) benzylamine

3,5-Bis (trifluoromethyl) benzylamine (5.00 g) and N- (benzyloxycarbonyloxy) succinimide (5.12 g) were dissolved in 50 ml of tetrahydrofuran and the reaction mixture was stirred at room temperature for 3 hours. The solvent was removed under reduced pressure and the product was dissolved in CH ₂ Cl ₂ . The solution was washed with 50 mL H ₂ O and 50 mL brine. Dry the organic layer over MgSO ₄ , filter, and remove the solvent under reduced pressure to give the title compound.

Step II N-Boc-N-methyl-3,5-bis (trifluoromethyl) benzylamine

The product of Step I above (6.87 g) was dissolved in 50 mL of anhydrous tetrahydrofuran and cooled to -78 ° C. 1.5 M LDA in tetrahydrofuran (14 mL) was added and the reaction mixture was stirred at -78 ° C for 30 minutes and then slowly added 2.98 g of methyl iodide. The reaction mixture was stirred at room temperature for 18 hours. The solvent was removed under reduced pressure and the product was purified by flash column chromatography (silica gel, cyclohexane / ethyl acetate 9: 1) to give the title compound.

Step III N-methyl-N-3,5-bis (trifluoromethyl) benzylamine

2.00 g of the product of Step II above was dissolved in 100 ml of C ₂ H ₅ OH and the protecting group was removed by adding a catalytic amount of 10% palladium on carbon and placing the solution under a hydrogen atmosphere. The catalyst was filtered off after 4 hours and the solvent was removed under reduced pressure. The title compound obtained is reacted further analogously to Examples 1A to 1D.

Concerning examples 27 and 29:

Preparation of Boc- (S-prolyl- (S) -N-methyl) -3- (2-maphthyl) alanyl-N-benzyl-N-methylamide (Formula IX, R _p = Boe, R ² = CH 3, R ³ = 2-naphthyl, Z = N (CH 3), R ⁴ = phenyl, R ⁵ = H)

The product of Example 1C (1.08 g) and iodomethane (1.04 mL, 2.38 G) were dissolved in 30 mL of dimethylformamide. Silver oxide (1.95 g) was added, the reaction mixture was heated to 60 ° C and stirred until no starting material remained as determined analytically by HPLC. The reaction mixture was cooled to room temperature, diluted to 200 mL with CHCl ₃ and washed with 2 x 100 mL 5% KCN (aq), 2 x 100 mL H ₂ O and 50 mL brine, then dried over anhydrous MgSO _{4. ) was} filtered and the solvent was removed under reduced pressure to give the title compound as a pure colorless glass.

The title compound is reacted further analogously to Example 1D.

Concerning example 28:

28.A. Preparation of Boc- (S) -3- (naphthyl) alanine 2-pyridyl ester (Formula IV, R _p = Boe, R ² = H, R ³ = 2-naphthyl, R _a = 2-pyridyloxy)

Boc- (S) -3- (2-naphthyl) alanine (1.00 g) and 2-hydroxypyridine (0.33 g) were dissolved in 5 ml of anhydrous pyridine and the solution was cooled to 0 ° C. Dicyclohexylcarbodiimide (0.72 g) was added and the reaction mixture was stirred at 0 ° C for 6 hours. The solvent was removed under reduced pressure and the product was dissolved in 20 ml of ethyl acetate, filtered and the solvent was removed under reduced pressure. The product was purified by flash column chromatography (silica gel, cyclohexane / ethyl acetate, 2: 1) to give the title compound. TLC (silica gel, cyclohexane / ethyl acetate, 1: 1) Rf = 0.41.

28.A.2 Preparation of Boc- [1- (S) -naphthalen-2-ylmethyl-2-oxo-4-phenylbutyl] amine [Formula VI, R _p = Boe, R ² = H, R ³ = 2 -naphthyl, Z = -CH ₂ -, R ⁴ = phenyl, R ⁵ = H]

The product of Example 28.A.1 (0.85 g) was dissolved in 10 ml of anhydrous tetrahydrofuran in a flame-dried flask and the solution was stirred under a nitrogen atmosphere. The solution was cooled to -78 ° C and a 2M solution of phenethylmagnesium bromide (2 mL) was slowly added. The reaction mixture was stirred at -78 ° C for 1 hour. 20 ml of saturated ammonium chloride solution are added and the product is extracted with ethyl acetate. Dry the organic layer over MgSO ₄ , filter, and remove the solvent under reduced pressure. The product was purified by flash column chromatography (silica gel, cyclohexane / ethyl acetate, 9: 1) to give the title compound: TLC (silica gel, cyclohexane / ethyl acetate, 4: 1) R f = 0.66.

The title compound was further reacted in analogy to Examples 1B to 1D.

To prepare in larger quantities, the reaction procedures of Examples 1A to 1D can be adjusted accordingly as outlined in the following Example 34.

Example 34

Preparation of 2-nitrophenylcarbamoyl - [(S) -prolyl] - [(S) -3- (2-naphthyl) alanyl] -N-benzyl-N-methylamide in large quantities:

Stage I (Example (A)

A 0.5 liter three-necked round-bottomed flask equipped with a mechanical stirrer, digital thermometer, dropping funnel, nitrogen inlet and outlet was charged in a cooling bath with 187.4 g of N-benzylmethylamine and cooled to 1-5 ° C (internal temperature). Ethyltrifluoroacetate (7.5 g) was added dropwise over 15 minutes, maintaining the internal temperature at 1-5 ° C. The dropping funnel was washed with a total of 7.5 mL of ethyl acetate in three equal portions (2.5 mL each) and added to the reaction mixture. Remove the cooling bath and allow the mixture to warm to room temperature (21-23 ° C) for 30 minutes. The mixture was stirred at room temperature for 30 minutes to give an oil.

A 4 L 4-neck round bottom flask equipped with a mechanical stirrer, digital thermometer, dropping funnel, nitrogen inlet and outlet was charged in a cooling bath with 394.0 g of Boc- (S) -3- (2-naphthyl) alanine and 5.6 L of ethyl acetate. The solution was cooled to -15 ° C (internal temperature) and added over 5 minutes

174.4 g of 4-methylmorpholine. The addition funnel was washed with 25 mL of ethyl acetate and added to the reaction mixture. The mixture was stirred for 10 minutes and a solution of 172.0 mL (181.12 g) of isobutyl chloroformate in 125 mL of ethyl acetate was added over 30 minutes while maintaining the internal temperature at -14 ° C to -16 ° C. The addition funnel was washed with 50 mL of ethyl acetate in two equal portions (25 mL each) and added to the reaction mixture. The suspension was stirred at -14 to -15 ° C for an additional 30 minutes. A solution of the above-prepared N-benzylmethylamine in 125 mL of ethyl acetate was added at a constant rate over 40 minutes while maintaining the internal temperature at -14 to -15 ° C. The addition funnel was washed with 50 mL of ethyl acetate in two equal portions (25 mL each) and added to the reaction mixture. After further stirring at the same temperature for an additional 1 hour with 10 minutes, 34.4 ml of a solution (36.22 g) of isobutyl chloroformate in 25 ml of ethyl acetate was added, maintaining the internal temperature at -14 to -16 ° C. The addition funnel was washed with 10 mL of ethyl acetate in two equal portions (5 mL each) and added to the reaction mixture. The suspension is stirred for an additional 15 minutes at -14 to -16 ° C. Add a solution of 37.4 g of N-benzylmethylamine (pretreated with 1.5 g of ethyltrifluoroacetate as above) in 25 mL of ethyl acetate at a constant rate over 10 minutes while maintaining the internal temperature at -14 to -15 °. C. The addition funnel was washed with 10 mL of ethyl acetate in two equal portions (5 mL each) and added to the reaction mixture. The reaction mixture was allowed to warm to room temperature (21-22 ° C) over 1 hour. The reaction mixture was then stirred for an additional 1 hour at room temperature (21-22 ° C). Add

2.5 l of water and stirring is continued for 5 to 10 minutes. The organic layer was separated and washed with 1.876 L of 1N hydrochloric acid and then with 1.81 of water. The organic layer was washed with 1.5 L of 5% aqueous sodium bicarbonate. The resulting organic layer was washed with 1.5 L of water and then 1.0 L of brine and filtered through a Buchner funnel to give 6.1 L of Boc- (S) -3- (2-naphthyl) alanyl-N 2 O solution.

-benzyl-N-methylamide in ethyl acetate. This solution was left overnight at room temperature under nitrogen for the next step reaction.

Stage II (Example 1B) A 4-neck round bottom flask equipped with a mechanical stirrer, digital thermometer, dropping funnel, and drying tube was charged in a cooling bath with a solution of 455.75 g of hydrogen chloride gas in 2.2 L of ethyl acetate. The solution is cooled to 10 ° C (internal temperature) and 6.1 l of the crude product from step I in ethyl acetate is added over 25-30 minutes while maintaining the internal temperature below 20 ° C. The mixture was allowed to warm to room temperature (22-23 ° C) and stirred at this temperature for an additional 3 hours. The reaction mixture is concentrated under reduced pressure (40 to 45 ° C, 13.3 to 14.66 kPa) until 5.0 L of solvent is removed, cooled to 20 to 22 ° C and stirred for 15 to 30 minutes. The solid was filtered on a Buchner funnel and washed with a total of 1.2 L of ethyl acetate in four equal portions of 300 mL. The solid is dried at 50-55 ° C (103.5 kPa) for 24 hours until a constant weight of pure (S) -3- (2-naphthyl) alanyl-N-benzyl-N-methylamide hydrochloride is obtained. Purity: 98.4% (HPLC), [α] D: + 24.8 ° (c = 1, methanol).

Stage III (Example IC) A 4-neck round bottom flask equipped with a mechanical stirrer, digital thermometer, dropping funnel was charged in a cooling bath with 332.0 g of the product of Stage II and 2.0 L of isopropyl acetate. The suspension is cooled to 10-12 ° C (internal temperature) using an ice-water bath. With vigorous stirring, 1.4 L of 5% aqueous sodium hydroxide is added over 10 minutes while maintaining the internal temperature at 10-12 ° C. The mixture was allowed to warm to 21-22 ° C over 30 minutes. The organic layer was separated and washed with 0.7 L of water and then 0.25 L of sodium chloride solution. The organic layer was dried over 100 g of anhydrous sodium sulfate and filtered through a Buchner funnel. The solids were washed with 90 ml of isopropyl acetate in three portions of 30 ml each. The organic layer was concentrated under reduced pressure (4-10 kPa, 43-45 ° C) until no further solvent distilled to give 0.35 L of (S) -3- (2-naphthyl) alanyl-N-benzyl- N-methylamide (free base) as an oil. This will be retained.

A 4-neck round bottom flask equipped with a mechanical stirrer, digital thermometer, dropping funnel, nitrogen inlet and outlet was charged in a cooling bath with 205.4 g of Boc- (S) -proline and 3.2 L of ethyl acetate. The mixture was stirred for 5 minutes until a solution was obtained. 125.6 g is added over 10 minutes

4-methylmorpholine while maintaining the internal temperature at 20-22 ° C. The funnel was washed with 25 mL of ethyl acetate and added to the reaction mixture. The solution is cooled to -15 ° C (internal temperature) and a solution of 132.9 g of isobutyl chloroformate in 75 mL of ethyl acetate is added over 25-30 minutes while maintaining the internal temperature at -14 to -16 ° C. The funnel was washed with 60 ml of ethyl acetate in three equal portions of 20 ml each and added to the reaction mixture. The suspension is stirred for an additional 30 to 35 minutes at -14 to -15 ° C. A constant rate of about 10 ml / min. 0.35 L of a solution of (S) -3- (2-naphthyl) alanyl-N-benzyl-N-methylamide in 0.35 L of ethyl acetate was added over 70 minutes while maintaining the internal temperature at -14 to -15 C. The funnel was washed with a total of 75 mL of ethyl acetate in three equal 25 mL portions and added to the reaction mixture. The reaction mixture was allowed to warm to room temperature (21-22 ° C) over 1 hour. The reaction mixture was stirred at room temperature (21-22 ° C) for an additional 1 hour. At 21 to 23 ° C, 3.0 L of water was added and the mixture was stirred for 5 to 10 minutes. The organic layer was separated and washed with 1.5 L of 1 M hydrochloric acid and then with 1.5 L of water. The resulting organic layer was washed successively

1.5 L of 5% aqueous sodium bicarbonate solution, 1.5 L of water and 1.0 L of sodium chloride solution. The organic layer was filtered through a Buchner funnel to give a 3.93 L solution of Boc- (S) -prolyl- (S) -3- (2-naphthyl) alanyl-N-benzyl-N-methylamide. This solution was stored at room temperature overnight under nitrogen atmosphere for the next step.

Stage IV (Example IC) A four-necked four-necked round-bottomed flask equipped with a mechanical stirrer, digital thermometer, dropping funnel, and drying tube was charged with a solution of 337.3 g of hydrogen chloride gas in 1.63 L of ethyl acetate in a cooling bath. The solution was cooled to 6 ° C (internal temperature) and 3.93 L of the crude product of Step III was added over 25-30 minutes while maintaining the internal temperature below 20 ° C. The funnel was washed with a total of 180 mL of ethyl acetate in three equal portions of 60 mL and added to the reaction mixture. The mixture was allowed to warm to room temperature (22-23 ° C) and stirred at this temperature for an additional 2 hours. The reaction mixture is concentrated under reduced pressure (40-44 ° C, 10.66 to 14.66 kPa) until 4.7 L of solvent is removed. The resulting oil (0.66 L) was dissolved in 1.4 L of water and extracted with 1.0 L of ethyl acetate. The organic layer was extracted with 0.2 L of water. The aqueous layers were combined and transferred to a five-liter four-necked round-bottom flask equipped with a mechanical stirrer, digital thermometer, dropping funnel, and cooling bath. The aqueous layer is cooled to 15 ° C (internal temperature) using an ice-water bath and a pre-cooled (20-21 ° C) solution of 120 g of sodium hydroxide in 1.2 L of water is added over 20-30 minutes while the internal the temperature is kept below 18 ° C (pH should be 9-10). The mixture was allowed to warm to room temperature (21-23 ° C) over 10 minutes and extracted with 3.0 L of isopropyl acetate. The organic layer was separated and the aqueous layer was extracted with a total of 1.0 L of isopropyl acetate with two equal portions of 0.5 L each. The combined organic layers were washed with 0.75 L of water and then with 1.5 L of sodium chloride solution. The organic layer was dried over 125 g of anhydrous sodium sulfate and filtered through a Btichner funnel. The solids were washed with a total of 100 mL of isopropyl acetate in two equal portions of 50 mL to give 5.02 L of (S) -prolyl- (S) -3- (2-naphthyl) alanyl-N-benzyl-N-methylamide. This solution is maintained under a nitrogen atmosphere for the next step.

Stage V (Example 1) A 4-neck round bottom flask equipped with a mechanical stirrer, digital thermometer, dropping funnel, nitrogen inlet and outlet was charged in a cooling bath with a 5.02 L solution of the product of Step IV in isopropyl acetate. The solution is cooled to 10 to 11 ° C (internal temperature) in an ice-water bath (bath temperature 6 to 7 ° C) and a solution of 156 g of 2-nitrophenylisocyanate in 0.5 L of isopropyl acetate is added over 20-30 minutes while the internal temperature is maintained below 17-18 ° C. The funnel was washed with a total of 50 mL of isopropyl acetate in two equal 25 mL portions and added to the reaction mixture. The mixture was allowed to warm to room temperature (22-23 ° C) and stirred at this temperature for an additional hour. The reaction mixture is filtered and concentrated under reduced pressure (40 to 45 ° C, 9.33 to 13.33 kPa) until no solvent distills. About 0.64 kg of the crude product was dissolved in 0.5 L of ethyl acetate / hexane (60:40 v / v) by heating to 40 ° C (bath temperature), cooled and packed onto a 8.5 column chromatography column. kg of silica gel. The column is eluted until the liquid level reaches silica gel. The flask was washed with a total of 0.9 L of ethyl acetate / hexane (60:40 v / v) in three equal portions of 0.3 L and loaded onto the column. Each time the column is eluted until the liquid level reaches silica gel. The column was eluted with 36.5 L of ethyl acetate / hexane (60:40 v / v) followed by 38 L of ethyl acetate. Fractions 16 to 24 containing the product were combined and the solvent was evaporated (39-44 ° C) until no solvent distilled. The resulting oil was suspended in 1.81 ethanol (190 degrees) and the solvents were evaporated (39-44 ° C). The residue was dissolved in 3.1 L of ethanol (190 degrees) by heating (bath temperature 40-45 ° C). 3.6 liters of solution are formed and this is cooled to 29-30 ° C (internal temperature) and added over 30 minutes to 13 liters of water which has previously been cooled to 7-8 ° C (internal temperature, bath temperature 0 to -30 ° C). 2 ° C), in a twelve-liter four-necked round-bottomed flask equipped with a mechanical stirrer, digital thermometer, dropping funnel, nitrogen inlet and outlet, and cooling bath while maintaining the internal temperature at 7-9 ° C. The funnel was washed with a total of 100 mL of ethanol (190 degrees) in two equal 50 mL portions and added to the suspension. The suspension was stirred at the same temperature for an additional 35 minutes and the solid was filtered through a polypropylene filter layer in a Buchner funnel. The solid is washed with a total of 3 L of water in three equal 1 L portions. The solid is dried on a polyethylene film in a vacuum oven at 42 to 43 ° C (42.5 kPa) until a constant weight (44 hours) of product is obtained.

2-nitrophenylcarbamoyl - [(S) -prolyl] - [(S) -3- (2-naphthyl) alanyl] -N-benzyl-N-methylamide as a yellow solid.

Purity: 99.4% (by HPLC 951068), [α] ²⁰ _D : -59.8 ° (c = 1, methanol).

The compounds of formula I and their pharmaceutically acceptable salts, hereinafter collectively referred to as compositions of the invention, exhibit tachykinin antagonist activity. In particular, the compositions of the invention exhibit significant potency of the NK-1 receptor tachykinin (substance P). The compositions of the invention are therefore useful as pharmaceuticals, for example as set forth below.

NK-1 receptor binding affinity can be demonstrated by the ability to displace [3 H] -ubstance P binding, for example as described in the following assay: Test I

Displacement of [ ³ H] -substance P binding from membranes of transfected Cos-7 cells with cloned human NK-1 receptor (hNK-1R).

Preparation of membranes containing hNK-1R

Transient expression of recombinant DNA into Cos-7 cells and subsequent cell collection is performed analogously to standard techniques (Sambrook et al., 1989, Kriegler 1990).

Membranes are prepared from transfected Cos-7 cells by homogenization at 10,000 rpm for 30 seconds using a Kinematica homogenizer. The resulting suspension is centrifuged at 28,000 xg for 30 minutes. The pellets were washed and resuspended twice in Tris-HCl (50 mM, pH 7.4) and centrifuged again. The final pellets are resuspended at 2 to 8 mg protein / ml in Tris-HCl (50 mM, pH 7.4) containing 5% glycerol and 500 µL aliquots are rapidly frozen in dry ice.

Binding of [ ³ H] substance P to membranes containing the hNK-1 R receptor

The membranes prepared as described above are kept in suspension at 70 ° C. Binding assays are performed in 1.2 ml micron polypropylene tubes containing 0.5 ml in final volume: binding buffer (composition in ggm ^-1 : chymostatin, 2, leupeptin, 4, bacitracin, 40, 2 mM MnCl ₂ , 0.1 % bovine serum albumin, 20 mM Hepes, pH 7.4), 400 μΙ membrane suspension (0.019 ± 0.003 mg protein per tube), 50 μΙ 50% dimethylsulfoxide (to total volume), 50 μΙ CP96.345 (Snider and j ., 1991) (10 μΜ) (for non-specific binding determination) or 510 μΙ of the test compound concentrate at various concentrations. 10 mM stock solutions of test compounds in 100% dimethylsulfoxide (DMSO) were prepared. These stock solutions were further diluted to 1 mM in 50% DMSO prior to use. Six concentrations of each test compound are used to obtain inhibition curves. All tests are performed in triplicate. Specific binding to NK-1 receptors is defined as the difference between the value found in the full binding tube and the tube in which non-specific binding was found. The reaction is initiated by the addition of a radioligand and incubated for 45 minutes at 24 ° C. The reaction is terminated by the addition of 500 µL of ice-cold Tris-HCl buffer (50 mM, pH 7.4). The binding mixture is quickly filtered through a Whatman GF / B filter film (soaked in 0.3% polyethyleneimine for 2-3 hours at room temperature). The tubes and filter foil are washed six times with 1 ml ice-cold buffer. Filter-bound radioactivity is determined using a Canberra Packard TopCount liquid scintillator. Microscint-40 is used as scintillation fluid. Binding parameters were calculated by the method of Munson and Rodbard, 1980 using LIGAND.

Initial protein experiments with human NK-1 receptor transfected Cos-7 cell membranes show that the specific binding of [ ³ H] substance P is usually> 70% of total binding and 3% of total radioactivity added to the incubation medium.

The attachment of [ ³ H] Substance P to the human NK-1 receptor / Cos-7 membrane is rapid, reaches equilibrium in 20 minutes and is stable up to 90 minutes at room temperature. Binding is measured after 45 minutes in all subsequent assays.

Saturation curves for the binding of [ ³ H] Substance P to the human NK-1 receptor / Cosh-7 membrane are measured after 45 minutes incubation at room temperature. The equilibrium dissociation constant (Kq = 85 ± 12 pM) and the number of binding sites (B _max = 537 ± 139) are determined by a non-linear iterative regression curve from at least three data simultaneously for each transfection using LIGAND (Munson et al., 1980) and arithmetic the average calculated from all ten transfections.

references:

Kriegler et al. (1990): Gene Transfer and Expression. A laboratory manual, Stockton Press.

Munson ea (1980): Anal. Biochem. 107: 220th

Sambrook et al. (1989) Molecular Cloning: A laboratory manual (2nd edition), Cold Spring Harbor Laboratory Press. Refs. Snider et al. (1991): Science 251: 435-436.

The compositions of the invention are effective in displacing [ ³ H] Substance P at concentrations of the order of Ki = about 0.01 to about 10.0 nM in this assay.

The pharmacological, for example, analgesic utility of the compositions of the invention as NK-1 receptor antagonists can also be demonstrated using standard test models, for example the following:

Test II: hyperalgesia model

A test group of 6 male Dunkin-Hartley guinea pigs (about 250 g) was injected intraplantarly with 100 μΙ of 1% carrageenan. Mechanical hyperalgesia is measured using a Ugo Basile Analgesymetra (250 g max. Applied to the paw) and the Response threshold is determined as the first sign of anxiety in the animal. Thermal hyperalgesia is determined by placing the animals in a perspex cage, applying a thermal stimulus from the ramp to the foot surface of the paw, and measuring the response time on the paws (Hargreaves et al., Pain 32, 77-88 (1988)). The response thresholds for mechanical and thermal stimuli are measured for both inflamed and non-inflamed paws.

Thermal / mechanical hyperalgesia is measured 24 hours after carrageenan injection. Test substance, i. j. composition of the invention in 10% DMSO

I vtragakante (1%) is then administered orally at different doses and the thermal / mechanical hyperalgesia is measured again after a further 3 hours.

In the above-described testing of the compositions of the invention, they have been found to be effective in reducing mechanical hyperalgesia at doses of the order of from about 0.1 to about 5.0 mg / kg p. about. and thermal hyperalgesia at doses of the order of from about 0.5 to about 5.0 mg / kg p. about.

The compositions according to the invention are therefore useful as medicaments, for example as tachykinin antagonists, in particular NK-1 (substance P), for example for the treatment of diseases or clinical conditions characterized or having aetiology characterized by excessive or undesired substance P-mediated activity.

They are particularly useful as analgesics or antinociceptive agents for the treatment of pain of various origins or aetiology. They are also useful as anti-inflammatory or anti-oedemic agents for the treatment of inflammatory reactions, diseases or conditions.

As for their analgesic potency, and unlike other prior art tachykinin antagonists such as NK-1, it has surprisingly been found that the compositions of the invention have significant or enhanced potency after oral administration. It has also been found that, unlike other prior art tachykinin antagonists, such as NK-1, they have a pronounced antinociceptive effect on the central nervous system following systemic administration, i. j. that they more easily penetrate the central nervous system.

In view of their analgesic / anti-inflammatory properties, the compositions of the invention are particularly useful for the treatment of inflammatory pain, for example, severe chronic pain. For example, they are useful for the treatment of pain, inflammation and / or swelling as a result of an injury, for example, burns, sprains, fractures and the like, as well as for surgical procedures, for example for the treatment of postoperative pain. They are further useful for the treatment of arthritis and rheumatic diseases, tenosynovitis, vasculitis and rheumatic joint pain, for example rheumatoid arthritis, as well as for the treatment of gout.

The compositions of the invention are further useful for the treatment of pain associated with angina, renal or biliary colic and menstruation.

The compositions of the invention are also useful for the treatment of pain associated with migraine. They are further useful as antiemetics for the treatment of vomiting, for example, vomiting caused by chemotherapy, poisons, pregnancy or migraine, as well as for the treatment of incontinence and gastrointestinal disorders such as gastric emptying retardation, dyspepsia, esophageal reflux and bloating.

The compositions of the invention are further useful for the treatment of chronic or obstructive diseases of the respiratory tract, for example for the control or prevention of bronchial edema, pulmonary mucosal secretion or airway hyperactivity, for example for use as therapeutic or prophylactic agents for the treatment of asthma. The compositions of the invention are useful for the treatment of atopic and non-atopic asthma, for example for the treatment of allergic asthma, exercise-induced asthma, occupational asthma, asthma caused by bacterial infection or medications, e.g. aspirin-induced asthma, as well as wheezing in infant syndrome.

Other inflammatory or obstructive respiratory diseases to which the present invention is applicable include pneumoconiosis (an inflammatory, usually occupational lung disease, often associated with repeated inhalation of dust) of any type or origin, including, for example, aluminosis, anthracosis, asbestosis, chalcose, ptilosis, siderosis, silicoses, tobacco and especially byssinosis.

Still other inflammatory or obstructive respiratory tract diseases for which the active compounds of the invention are useful include adult respiratory distress syndrome (ARDS), chronic obstructive pulmonary or respiratory disease (COPDS or COAD), and bronchitis. The active compounds according to the invention can also be used for the treatment of allergic and vasomotor rhinitis.

The compositions of the invention are further indicated for use in the treatment of:

- central nervous system disorders, in particular anxiety conditions, for example for the treatment of anxiety, depression, psychosis, schizophrenia, panic attacks, phobiasis such as agrophobia, stress-induced somatic disorders and addictive disorders such as alcoholism or cocaine abuse,

non-neurodegenerative disorders such as dementia, including senile dementia, Alzheimer's disease and Down's syndrome.

demyelinating diseases such as MS, ALS, and other neuropathological disorders such as peripheral neuropathy, diabetic and chemotherapeutic-induced neuropathy.

The compositions of the invention are further indicated for use in the treatment of diseases or conditions associated with immune system dysfunction, for example autoimmune diseases, particularly when associated with inflammatory, swelling or nociceptive cases. Specific diseases or conditions of this category include, for example, autoimmune hematological disorders (including, for example, haemolytic anemia, aplastic anemia, red blood cell anemia and idiopathic thrombocytepenia), systemic lupus erythematosus, polychonritis, scleredema, Wegener's granulomatosis, hepatitis chronitis, myermatitis; , Steven-Johnson syndrome, idiopathic sprue, autoimmune inflammatory bowel disease (including, for example, ulcerative colitis and Crohn's disease), endocrine ophthalmopathy, Graves' disease, sarcoidosis, multiple sclerosis, primary biliary cirrhosis, juvenile diabetes mellitus, keratitis, keratitis interstitial lung fibrosis, psoriasis, psoriatic arthritis and glomerulonephritis (with and without nephrotic syndrome, for example including idiopathic nephrotic syndrome or minimal change nephropathy), as well as vasculitis. The compositions of the invention may also be used as immunosuppressants or immunosuppressive adjuvants, for example, for use in conjunction with other immunosuppressants, e.g., cyclosporine or immunosuppressive macrolide therapy, to suppress allograft rejection, e.g., following allogeneic transplants, such as kidney, liver, , heart, lung transplantation, or both heart and lung transplantation.

The compositions of the invention are further indicated for use in the treatment of allergic diseases and conditions, for example, skin, eyes, nasopharynx or the gastrointestinal tract, particularly when such diseases or conditions are accompanied by inflammatory, swelling or nociceptive reactions. Examples of such diseases or conditions are, for example, eczema, hypersensitivity such as poison allergy, contact dermatitis, conjunctivitis, juvenile conjunctivitis, dry keratoconjunctivitis, uratria and other eczematous dermatoses.

The compositions of the invention are also useful in the treatment of blood flow disorders caused by vasodilation and vasospastic diseases such as angina, migraine and Reynaud's disease.

In addition, the compositions of the invention have also been found to be effective in blocking P-glycoprotein; They may be used as adjuvants or as co-therapy and drugs of another therapeutic category, for example:

to enhance the efficacy or sensitivity of other chemotherapeutic therapy, in particular antimicrobial (e.g., antibacterial, antiviral, antifungal or antiprotozoidal) chemotherapy, AIDS chemotherapy, and in particular anti-cancer or anti-tumor (e.g. antineoplastic or cytostatic) chemotherapy. They are therefore indicated for use, for example, as a means of lowering the usual chemotherapeutic doses, for example in the case of antineoplastic or cytostatic therapy, as a means of reducing the overall toxicity of drugs and in particular as a means of altering or reducing resistance, including both innate and acquired resistance to chemotherapy.

to enable or enhance other central nervous system drug therapies, for example to increase blood-brain barrier drug penetration, for example, to allow or enhance other psychotropic drug therapies, for example, to be administered in conjunction with other analgesic or psychomotor stimulators or depressants, e.g. treatment of neurodegenerative diseases, including Parkinson's disease, Alzheimer's disease and the like, as well as chemotherapy associated with brain tumors,

as antiparasitic, in particular antiprotozoidic agents, for example especially against the organisms of the genera Toxoplasma (e.g. Toxoplasma gondii) and Plasmodia (e.g. Plasmodium falciparum).

For the above indications, the dosages of the compositions of the invention will, of course, vary depending upon, for example, the host, the route of administration, and the type and severity of the condition to be treated, as well as the relative efficacy of the particular composition used. In general, however, it has been found that sufficient results are obtained in animals, for example in the treatment of pain, migraine and vomiting, at daily dosages of about 0.1 to about 10 mg / kg p.o. In larger mammals, for example humans, a daily dose in the range of about 7.0 to about 0.1 is indicated

700 mg / day p.o., for example about 100 mg / day p.o., and suitably administered in a single dose or in divided doses up to four times a day or in a slow release form, for example, to treat pain, migraine and vomiting. Thus, oral dosage forms suitably contain from about 1.5 to about 150 or 700 mg, for example from about 25 to 100 mg of a composition of the invention mixed with an appropriate pharmaceutically acceptable diluent or carrier.

Because of the relatively low solubility of the compositions of the invention, they are formulated for oral administration into a composition comprising a hydrophilic phase (e.g., propylene glycol / ethanol), a hydrophobic phase (e.g., vegetable oil based on mono- or di-triglycerides such as commercially available MAISINE). an active agent (for example, a polyoxyhydrogenated vegetable oil such as commercially available under the name CREMOPHOR). Formulations for intravenous administration may be prepared by dissolving the selected composition of the invention in ethanol together with an appropriate surfactant (e.g. CREMOPHOR RH 40). The following example illustrates the preparation of galenic forms suitable for oral administration:

component

1. prostr. according to you, e.g.

Example compound 1

2. propylene glycol

3. Corn oil mono-di-triglycerides, e.g. Maisie

4. polyoxyl-40-hydrogenated castor oil, e.g. CREMOPHOR RH 40

5. ethanol, anhydrous amount / unit dose

100.00 mg

94.70 mg

319.90 mg

383.70 mg

94.70 mg total 993.00 mg

Component 4 is heated to 40 ° C until liquefied. Components 2, 3 and 5 are added and the whole mixture is mixed in a conventional manner until a clear solution is obtained. To the solution obtained, the milled component 1 is added in finely divided form, for example the compound of Example 1 (free base, amorphous), optionally at a lower temperature, and mixed until a clear solution is printed. The product is suitable for drinking as a drinking solution. Alternatively, the mixture may be formulated into soft or hard gelatin capsules, for example each capsule contains 50 or 100 mg of component 1.

The compositions of the invention may alternatively be administered, for example, topically in the form of a cream, gel or soil, for example for the treatment of skin conditions as described above, or by inhalation, for example in dry powder form, for the treatment of obstructive or inflammatory diseases of the airways or any by another suitable method, for example by injection or infusion.

A preferred composition of the invention is the product of Example 1. In one series of experiments, the ED50 values for Test II above were of the order of 0.73 ± 0.09 mg / kg p.o. for mechanical hyperalgesia and 1.75 ± 0.64 mg / kg p.o. for thermal hyperalgesia. The determined ED50 for aspirin in the same assay is of the order of about 30 mg / kg for mechanical hyperalgesia and about 100 mh / kh for thermal hyperalgesia. Thus, the indicated oral doses of the compound of Example 1 administered as an analgesic are of the order of 1/40 to 1/50 doses of clinically used aspirin.

Another preferred composition of the invention, the product of Example 17. In one series of experiments were determined ED ₅₀ for the test II, cited above, for this compound in the order of 1.0 mg / kg for mechanical hyperalgesia. Thus, the indicated oral doses of the compound of Example 17 administered as an analgesic are of the order of 1/30 of the clinically used aspirin.

The present invention also relates to:

1) A composition according to the invention for use as a medicament, for example for use as an NK-1 antagonist (substance P), for example for use in any of the above indications, in particular for use as an analgesic, anti-inflammatory or anti-inflammatory agent or for use in the treatment of allergic conditions; reactions, for example in rhinitis or in the treatment of vomiting.

2) A pharmaceutical composition comprising a composition of the invention as an active ingredient together with a pharmaceutically acceptable diluent or carrier.

3) A method of treating any of the above indications in a subject in need of such treatment, the method comprising administering to the subject an effective amount of a composition of the invention.

Claims (12)

PATENT CLAIMS A compound of formula I R ^{2 Cl 2} _X 3 R ⁴ I I ii L N - CHC - z - CHR ⁵ (b) (c) (I) wherein R ¹ is phenyl mono- or di-substituted with one or two substituents selected from the group consisting of halogen, nitro, cyano, trifluoromethyl, hydroxy, methoxy, hydroxymethyl, methoxymethyl, methoxycarbonyl, carbamoyl, N-methyl, n is zero or 1, X ¹ is oxygen, sulfur or = NCN, X ² and X ³ are each independently O or S, R ² is H or methyl, R ³ is phenyl, halogen-substituted phenyl, 2-naphthyl, 1H-indol-3-yl or 1-methylindol-3-yl, Z is -N (CH ₃ ) - or -CH ₂ -, R ⁴ is phenyl, 3,5-bis (trifluoromethyl) phenyl or pyridyl; and R ⁵ is hydrogen, phenyl, 3,5-bis (trifluoromethyl) phenyl, wherein when X ³ is sulfur, Z is -N (CH ₃ ) -, or an acid salt thereof. A compound of formula I as claimed in claim 1, wherein R ¹ is 2-halophenyl or 2-nitrophenyl, n is zero, X ² and X ³ are each oxygen, R ⁴ is phenyl or pyridyl, R ⁵ is hydrogen, phenyl or pyridyl; X ¹ , R ² , R ³ and Z are as defined in claim 1, or an acid salt thereof. A compound of the formula I as claimed in claim 1, wherein R ¹ is a group of the formula wherein R ^1a is a trifluoromethyl group, a halogen atom, a methoxy group or a nitro group, and R ^1b is hydrogen, trifluoromethyl, halogen, methoxy or nitro, n is 1, X ² and X ³ are each oxygen, R ³ - is a halogen-substituted phenyl, 2-naphthyl, 1H-indol-3-yl or 1-methyl-indol-3-yl group, Z is -N (CH ₃ ) - and X ¹ , R ² , R ⁴ and R ⁵ have the meanings set forth in claim 1, or an acid salt thereof. A compound of formula I as claimed in claim 1, wherein R ¹ is 2-nitrophenyl, n is zero, X ¹ , X ² and X ³ are each oxygen, R ² is hydrogen, R ³ is 2-naphthyl, Z is -N (CH ₃ ) -, R ⁴ is phenyl and R ⁵ is hydrogen. A compound of the general formula given in claim 1, wherein ^R1 is 2- (methoxymethyl) phenyl, ^R2 is hydrogen, n is zero, X ^1, X ² and X ³ are each oxygen, ^R3 is 2-naphthyl, Z is -N _(CH3) -, R ⁴ is phenyl and R ⁵ is hydrogen. A compound of formula I as claimed in claim 1, wherein a) R ¹ is 2-nitrophenyl, n is zero, X ² and X ³ are each oxygen, R ² is hydrogen, R ³ is 2-naphthyl, Z is -N (CH ₃ ) - a -X ¹ is a sulfur atom, R ⁴ is phenyl and R ⁵ is a hydrogen atom, -X ¹ is = NCN, R ⁴ is phenyl and R ⁵ is hydrogen, -X ¹ is an oxygen atom and R ⁴ and R ⁵ are each 2-pyridyl, -X ¹ is an oxygen atom, R ⁴ is 2-pyridyl, and R ⁵ is a hydrogen atom, or -X ¹ is a sulfur atom, R ⁴ is 2-pyridyl, and R ⁵ is a hydrogen atom, or b) n is zero, X ¹ , X ² and X ³ are each oxygen, R ² is hydrogen, R ³ is 2-naphthyl, Z is -N (CH ₃ ) -, R ⁴ is phenyl, R ⁵ is a hydrogen atom and R ¹ is 2-chlorophenyl, 4-nitrophenyl, 2-cyanophenyl, 3-cyanophenyl, 4-fluorophenyl, 2- (methoxycarbonyl) phenyl, 3-nitrophenyl, 2- (methylcarbamoyl) phenyl, 2-carbamoylphenyl, 2-hydroxyphenyl or 2-hydroxymethylphenyl, or c) R ¹ is 2-nitrophenyl, n is zero, X ¹ , X ² and X ³ are each oxygen, R ³ is 2-naphthyl, R ⁴ is phenyl, R ⁵ is hydrogen and -R ² is methyl and Z is -N (CH ₃ ) -, or -R ² is a hydrogen atom and Z is -CH ₂ -, or d) R ¹ is 2-nitrophenyl, n is zero, X ¹ , X ² and X ³ are each oxygen, R ² is hydrogen, R ³ is 2-naphthyl, Z is -N (CH ₃ ) -, R ⁵ is hydrogen and R ⁴ is 1H-indol-3-yl or 3,4-dichlorophenyl, or e) n is 1, X ¹ is sulfur, X ² and X ³ are each oxygen, R ² is hydrogen, R ³ is 2-naphthyl, Z is -N (CH ₃ ) -, R ⁴ is phenyl, R ⁵ is hydrogen, R ¹ is 2-chlorophenyl, 2-trifluoromethylphenyl or 2-bromophenyl; or f) R ¹ is 2-chlorophenyl, n is 1, X ² and X ³ are each oxygen, R ² is hydrogen, R ³ is 2-naphthyl, Z is -N (CH ₃ ) -a -X ¹ is a sulfur atom and R ⁴ and R ⁵ are each 2-pyridyl, -X ¹ is a sulfur atom, R ⁴ is 2-pyridyl. and R ⁵ is a hydrogen atom, -X ¹ is an oxygen atom, R ⁴ is phenyl and R ⁵ is a hydrogen atom, -X ¹ is a sulfur atom, R ⁴ is 3,5-bis (trifluoromethyl) phenyl and R ⁵ is a hydrogen atom, or -X ¹ is a sulfur atom and R ⁴ and R ⁵ are each phenyl, or g) n is 1, X ¹ is a sulfur atom, X ² and X ³ are each an oxygen atom, Z is -N (CH ₃ ) -, R ⁴ is phenyl, R ⁵ is a hydrogen atom and -R ¹ is 2-nitrophenyl, R ² is methyl and R ³ is 2-naphthyl, -R ¹ is 2-chlorophenyl, R ² is hydrogen and R ³ is 3,4-dichlorophenyl or 1-methylindol-3-yl, or an acid salt thereof. A compound of formula I as claimed in claim 1, wherein the carbon atoms (a) and (b) and, when R ⁴ and R ⁵ are different and R ⁵ is other than a hydrogen atom, the carbon atom (a) have each (S) and wherein R ¹ to R ⁵ , X ¹ to X ³ , Z are as defined in any one of claims 1 to 3 or 6, or an acid salt thereof. A compound of formula I as claimed in claim 1, wherein the carbon atoms (a) and (b) have each (S) -configuration and wherein R ¹ to R ⁵ , X ¹ to X ³ , for Z have the meanings specified in claim 4 or 5. - A process for the preparation of a compound of formula I as defined in claim 1 or an acid salt thereof, comprising reacting a compound of formula II (H) wherein R ² to R ⁵ , X ² , X ³ and Z are as defined in claim 1, with a compound of formula III R ¹ '- (CH ₂ ) -N = C = X ¹ (III) wherein R ¹ ' is a phenyl group mono- or di-substituted with one or two substituents selected from the group consisting of halogen, nitro, cyano, trifluoromethyl and X ¹ has the meanings given in claim 1, optionally removing the protecting group from the compound thus obtained wherein R ¹ 'is a phenyl group substituted with a protected hydroxy group and / or a protected hydroxymethyl group. and / or converting the compound so obtained wherein R ¹ 'is a phenyl group substituted with a methoxycarbonyl group to the corresponding compound wherein R ¹ ' is a phenyl group substituted with a carbamoyl group or an N-methylcarbamoyl group, and the compound of formula I thus obtained is isolated in free form or in acid salt form. A pharmaceutical composition comprising a compound of formula I as defined in any one of claims 1 to 8, or a pharmaceutically acceptable acid salt thereof together with a pharmaceutically acceptable diluent or carrier. A compound of formula I as defined in any one of claims 1 to 8, or a pharmaceutically acceptable acid salt thereof, for use as a medicament. A method of treating pain or inflammation in a subject in need thereof, comprising administering to said subject an analgesically or anti-inflammatory effective amount of a compound as defined in any one of claims 1 to 8, or a pharmaceutically acceptable acid salt thereof.